Tectonic Therapeutic (TECX) Total Non-Current Liabilities (2017 - 2023)
Tectonic Therapeutic (TECX) reported Total Non-Current Liabilities of $43.4 million for Q4 2023, up 1221.0% quarter-over-quarter from $3.3 million in Q4 2017.
Tectonic Therapeutic (TECX) Total Non-Current Liabilities (2017 - 2023) Analysis & Trends
Tectonic Therapeutic (TECX) has 2 years of Total Non-Current Liabilities data on file, last reported at $43.4 million in Q4 2023.
- Total Non-Current Liabilities for Q4 2023 came in at $43.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $43.4 million (changed N/A YoY), and the FY2023 annual result was $43.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities grew to $43.4 million in Q4 2023 per TECX's latest filing, from $3.3 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $43.4 million in Q4 2023 and troughed at $43.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | Tectonic Therapeutic | 528.16 Mn | 291.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 43.41 Mn |
| Dec 31, 2017 | 3.29 Mn |